1 active not recruiting, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Terminated 1 |
Follow Shr3162: new trials by email Literature Review of Shr3162 trials Research Report on Shr3162
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo, Abiraterone acetate and Prednisone - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 496 | 2021-03-18 | 2024-12-31 |
| A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Fluzoparib, Placebo - Metastatic Pancreatic Cancer | Phase 3 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 5 | 2020-08-19 | 2024-03-28 |
Jiangsu HengRui Medicine Co., Ltd. (2)
China (2) · Australia (1) · Belgium (1) · Czechia (1) · France (1) · Hungary (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1) · United States (1)
Yupei Zhao, Ph.D (1)